Abstract
Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive and fatal neuromuscular disease; the majority of ALS patients die within 2-5 years of receiving a diagnosis (1). Familial ALS, a hereditary form of the disease, accounts for 5%-10% of cases, whereas the remaining sporadic cases have no clearly defined etiology (1). ALS affects persons of all races and ethnicities; however, whites, males, non-Hispanics, persons aged >60 years, and those with a family history of ALS are more likely to develop the disease (1-3). No cure for ALS has yet been identified, and the lack of proven and effective therapeutic interventions is an ongoing challenge. Current treatments available do not cure ALS but have been shown to slow disease progression. Until recently, only one drug (riluzole) was approved to treat ALS; however, in 2017, the Food and Drug Administration approved a second drug, edaravone (4).
Citations
Nov 15, 2018·International Journal of Environmental Research and Public Health·Germán Sánchez-DíazVerónica Alonso-Ferreira
Mar 21, 2019·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Rituparna BhattacharyaPaul Mehta
Nov 23, 2018·Acta Neuropathologica·Madelyn E McCauley, Robert H Baloh
Jul 30, 2019·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·James L Nuzzo
Oct 18, 2019·Muscle & Nerve·Jeremy ShefnerStephen Apple
Dec 14, 2018·Translational Neurodegeneration·William R SwindellDorothy Ko
May 19, 2020·Clinical EEG and Neuroscience·Xiaoqian YuEmanuel Donchin
May 20, 2020·PLoS Genetics·Dominic HollandAnders M Dale
May 31, 2020·International Journal of Molecular Sciences·Yeomin Yun, Yoon Ha
Jul 3, 2020·Journal of Personalized Medicine·Owen ConnollyStephanie Duguez
Aug 21, 2020·Medicinal Research Reviews·Michail S KukharskyVladimir L Buchman
Sep 11, 2019·Nature Reviews. Neurology·Yujun HouVilhelm A Bohr
Mar 3, 2020·Frontiers in Physiology·Sandra Carrera-JuliáEraci Drehmer
Dec 3, 2018·Translational Neurodegeneration·William R SwindellDorothy Ko
Jun 26, 2020·Frontiers in Molecular Neuroscience·Ravinder Malik, Martina Wiedau
Jul 20, 2019·BMC Neurology·Koji FujitaYuishin Izumi
Mar 5, 2020·Journal of Patient Experience·Lindsay RechtmanPaul Mehta
Nov 22, 2018·MMWR. Morbidity and Mortality Weekly Report·Paul MehtaKevin Horton
Mar 20, 2019·PloS One·Chih-Hsiung HsiehChih-Yu Chao
Apr 16, 2020·Frontiers in Bioengineering and Biotechnology·David X MedinaRachael W Sirianni
Oct 15, 2019·Clinical Pharmacology in Drug Development·Irfan QureshiRobert M Berman
Sep 10, 2020·Acta Neurologica Scandinavica·Kyla A McKayFabian Taube
Oct 29, 2020·The American Journal of Hospice & Palliative Care·Ambereen K MehtaMartina Wiedau-Pazos
Jan 6, 2021·Pharmaceuticals·HaEun Cho, Surabhi Shukla
Jan 23, 2021·Scientific Reports·Amirali ToossiVivian K Mushahwar
Dec 3, 2020·ERJ Open Research·Petra KotanenWaltteri Siirala
Jul 13, 2020·Ageing Research Reviews·Cinzia VolontéSebastiano Cavallaro
Apr 1, 2021·Genetics·Dominic HollandAnders M Dale
Jul 16, 2021·Biopreservation and Biobanking·Marianna J BledsoeWendy E Kaye
Jul 14, 2021·Muscle & Nerve·Marinella D GaleaRichard S Bedlack
May 29, 2020·ACS Chemical Neuroscience·Andrea I KrahnAlison D Axtman
Aug 24, 2021·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Paul MehtaKevin Horton
Sep 30, 2021·NPJ Genomic Medicine·Allison A DilliottRobert A Hegele
Mar 4, 2020·Neuro-degenerative Diseases·Helder VieiraLuis Coelho
Jan 12, 2022·Annals of Clinical and Translational Neurology·Jonathan S KatzJonathan D Glass
Jan 14, 2022·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Paul MehtaD Kevin Horton